Dupilumab rapidly improves asthma control in predominantly anti‐IL5/IL5R pretreated Austrian real‐life severe asthmatics

Dupilumab is a monoclonal antibody against the IL‐4 receptor alpha which has shown efficacy in T2 high severe asthmatics in phase 3 randomized controlled trials. The purpose of this real‐life study is to demonstrate the real‐life effectiveness of dupilumab in Austrian severe asthma patients. We retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Renner, Andreas, Marth, Katharina, Patocka, Karin, Idzko, Marco, Pohl, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342226/
https://www.ncbi.nlm.nih.gov/pubmed/33960689
http://dx.doi.org/10.1002/iid3.434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342226/
https://www.ncbi.nlm.nih.gov/pubmed/33960689
http://dx.doi.org/10.1002/iid3.434

Ejemplares similares